journal
https://read.qxmd.com/read/39387707/the-management-of-new-onset-atrial-fibrillation-in-critical-illness-an-update-on-current-therapeutic-options
#1
JOURNAL ARTICLE
Zhe Wang, Jiang Li, Yihong Sun
PURPOSE OF REVIEW: New-onset atrial fibrillation (NOAF) is the most prevalent arrhythmia among critically ill patients, correlating with heightened morbidity and mortality rates. Current evidence for managing NOAF in this patient population is limited. RECENT FINDINGS: Numerous meta-analyses have been conducted to assess the efficacy of atrial fibrillation treatments in acute settings, including rate or rhythm control strategies, anticoagulation, and intensive care interventions...
October 10, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39387703/ablation-options-for-sub-epicardially-located-ventricular-substrates-responsible-for-ventricular-tachycardia-where-is-it-all-headed
#2
JOURNAL ARTICLE
Jason S Sperling, Pasquale Santangeli
PURPOSE OF REVIEW: Patients with nonischemic and ischemic cardiomyopathy (NICM and ICM) exhibit re-entrant tachycardias related to scar tissue in subepicardial, in addition to typical subendocardial locations. Control of ventricular arrhythmias related to these targets has remained elusive despite advances in mapping and ablation technology. RECENT FINDINGS: Percutaneous epicardial ablation is the standard after failed endocardial ventricular ablation, but recurrence rates are disappointing...
October 10, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39365281/electrographic-flow-mapping-of-atrial-fibrillation
#3
JOURNAL ARTICLE
Steven Castellano, Melissa H Kong
PURPOSE OF REVIEW: A low ceiling of efficacy exists for the treatment of persistent atrial fibrillation via pulmonary vein isolation without adjunctive ablations, which is likely because they do not target an individual patient's specific underlying disease mechanisms. Electrographic flow (EGF) mapping is the first system that reliably displays wavefront propagation through the atria. It is a promising tool for localizing sources of atrial fibrillation, guiding targeted ablation, and visualizing conduction through the atrial substrate...
September 23, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39356277/the-role-of-advanced-physiological-guidance-in-contemporary-coronary-artery-disease-management
#4
JOURNAL ARTICLE
Daniel Munhoz, Kazumasa Ikeda, Frederic Bouisset, Koshiro Sakai, Atomu Tajima, Takuya Mizukami, Jeroen Sonck, Nils P Johnson, Carlos Collet
PURPOSE OF REVIEW: This review evaluates the emerging role of the pullback pressure gradient (PPG) as a standardized metric for assessing coronary artery disease (CAD) patterns and its implications for clinical decision-making when managing patients undergoing percutaneous coronary interventions (PCIs). By integrating PPG with existing physiological assessments, this review highlights the potential benefits of PPG in predicting treatment outcomes and refining therapeutic strategies for CAD...
September 20, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39356281/pathophysiology-and-clinical-implications-of-coronary-artery-calcifications
#5
JOURNAL ARTICLE
Luca Saba, Francesco Costa, Riccardo Cau
PURPOSE OF REVIEW: To provide a summary of current understanding of coronary artery calcifications (CACs), outlining the role of calcium in atherosclerosis to comprehend the clinical implications of CAC. RECENT FINDINGS: CAC serves as a reliable indicator of coronary artery disease (CAD) and it is associated with cardiovascular events. In recognition of its significance, recent global guidelines have integrated CAC assessment into risk evaluation protocols, highlighting its role as a noninvasive tool for evaluating and stratifying patients' risk for cardiovascular events...
September 16, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39254647/expanding-revascularization-trials-to-women-and-underserved-minorities-and-shifting-to-patient-centered-outcomes-recharge-trials-program
#6
JOURNAL ARTICLE
Bjorn Redfors, John A Spertus, Clyde Yancy, Ruth Masterson-Creber, Gregg W Stone, Mario F L Gaudino
PURPOSE OF REVIEW: We review the limited available evidence informing coronary revascularization decisions in women and minorities, and introduce the RECHARGE trial program, which consists of two separate but integrated parallel multicenter, randomized trials comparing coronary artery bypass grafting (CABG) to percutaneous coronary intervention (PCI), one exclusively enrolling women (RECHARGE:Women) and one exclusively enrolling Black or Hispanic patients (RECHARGE:Minorities). RECENT FINDINGS: The extensive evidence base supporting coronary revascularization suffers from under-representation of women, minorities and minoritized populations, and the use of heterogeneous primary composite outcomes whose components have varying strengths of association with prognosis and quality-of-life (QOL)...
August 20, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39254490/robotic-mitral-surgery-recent-advances-and-outcomes
#7
JOURNAL ARTICLE
Makoto Hibino, Douglas A Murphy, Michael E Halkos
PURPOSE OF REVIEW: This review explores recent advancements in robotic cardiac surgery, specifically focusing on its application in diverse mitral valve surgeries. The aim is to provide an overview of current clinical practices and supporting evidence in this evolving field. RECENT FINDINGS: A literature review indicates a 30% surge in robotic mitral valve repair from 2015 to 2021, paralleled by a decline in sternotomy-based repair per the STS database. Robotic mitral valve repair consistently shows effective and safe outcomes, with comparable mortality but lower morbidity risks than sternotomy and thoracotomy...
August 20, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39195569/acute-on-chronic-inflammation-in-acute-myocardial-infarction
#8
JOURNAL ARTICLE
Michael A Matter, Tristan Tschaikowsky, Barbara E Stähli, Christian M Matter
PURPOSE OF REVIEW: Acute myocardial infarction (AMI) is heralded by chronic inflammation and entails an excessive burst of acute-on-chronic inflammation (AoCI). This review describes the evolution from understanding atherosclerosis as a chronic inflammatory disease, to recent efforts in optimizing anti-inflammatory therapy to patients with AMI. It highlights the challenges and opportunities in selecting the optimal patient with AMI to derive maximal benefit from early anti-inflammatory therapy...
August 20, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39360632/is-it-feasible-to-treat-atrial-fibrillation-at-the-time-of-minimally-invasive-coronary-artery-bypass-grafting
#9
JOURNAL ARTICLE
Stephen D Waterford, Niv Ad
PURPOSE OF REVIEW: Coronary artery bypass grafting remains the most common operation performed by cardiac surgeons. As a result, a cardiac surgeon with a typical practice will most commonly encounter atrial fibrillation when performing coronary artery bypass grafting. In this review, we first emphasize the importance of treating atrial fibrillation in patients undergoing coronary bypass grafting. We review benefits of concomitant surgical ablation and its importance relative to complete coronary revascularization...
August 14, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39360617/lipoprotein-a-is-a-highly-atherogenic-lipoprotein-pathophysiological-basis-and-clinical-implications
#10
JOURNAL ARTICLE
Elias Björnson, Martin Adiels, Jan Borén, Chris J Packard
PURPOSE OF REVIEW: Lipoprotein(a) has been identified as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. However, as reviewed here, there is ongoing debate as to the key pathogenic features of Lp(a) particles and the degree of Lp(a) atherogenicity relative to low-density lipoprotein (LDL). RECENT FINDINGS: Genetic analyses have revealed that Lp(a) on a per-particle basis is markedly (about six-fold) more atherogenic than LDL...
August 14, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39356274/redo-coronary-artery-bypass-grafting-when-and-how
#11
JOURNAL ARTICLE
Benjamin Yang, Marijan Koprivanac, Faisal G Bakaeen
PURPOSE OF REVIEW: Redo coronary artery bypass grafting (CABG) remains technically challenging with significant procedural risk but may be the best option for patients in whom repeat revascularization is indicated. This review summarizes the latest data regarding risk of redo CABG, who should receive this surgery, and how to achieve best outcomes. RECENT FINDINGS: Over the past two decades, the risk of performing redo CABG has declined and is approaching that of primary CABG in the hands of experienced surgeons...
August 13, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39195561/coronary-artery-bypass-grafting-in-acute-coronary-syndromes-modern-indications-and-approaches
#12
JOURNAL ARTICLE
Sigrid Sandner, Alissa Florian, Marc Ruel
PURPOSE OF REVIEW: Acute coronary syndromes (ACS) are a leading cause of morbidity and mortality worldwide, with approximately 1.2 million hospitalizations annually in the U.S. This review aims to explore the contemporary evidence regarding revascularization strategies, including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), in ACS patients. It also addresses the unresolved questions concerning the optimal procedural aspects of surgery and antithrombotic therapy for secondary prevention postsurgery...
August 12, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39360655/lipoprotein-a-is-a-highly-atherogenic-lipoprotein-pathophysiological-basis-and-clinical-implications
#13
REVIEW
Elias Björnson, Martin Adiels, Jan Borén, Chris J Packard
PURPOSE OF REVIEW: Lipoprotein(a) has been identified as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. However, as reviewed here, there is ongoing debate as to the key pathogenic features of Lp(a) particles and the degree of Lp(a) atherogenicity relative to low-density lipoprotein (LDL). RECENT FINDINGS: Genetic analyses have revealed that Lp(a) on a per-particle basis is markedly (about six-fold) more atherogenic than LDL...
November 1, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39360654/is-it-feasible-to-treat-atrial-fibrillation-at-the-time-of-minimally-invasive-coronary-artery-bypass-grafting
#14
REVIEW
Stephen D Waterford, Niv Ad
PURPOSE OF REVIEW: Coronary artery bypass grafting remains the most common operation performed by cardiac surgeons. As a result, a cardiac surgeon with a typical practice will most commonly encounter atrial fibrillation when performing coronary artery bypass grafting. In this review, we first emphasize the importance of treating atrial fibrillation in patients undergoing coronary bypass grafting. We review benefits of concomitant surgical ablation and its importance relative to complete coronary revascularization...
November 1, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39360653/complex-issues-in-coronary-artery-surgery
#15
EDITORIAL
Marc Ruel, Robert Roberts
No abstract text is available yet for this article.
November 1, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39356276/high-lipoprotein-a-is-a-risk-factor-for-peripheral-artery-disease-abdominal-aortic-aneurysms-and-major-adverse-limb-events
#16
REVIEW
Peter E Thomas, Signe Vedel-Krogh, Pia R Kamstrup
PURPOSE OF REVIEW: To summarize evidence from recent studies of high lipoprotein(a) as a risk factor for peripheral artery disease (PAD), abdominal aortic aneurysms (AAA), and major adverse limb events (MALE). Additionally, provide clinicians with 10-year absolute risk charts enabling risk prediction of PAD and AAA by lipoprotein(a) levels and conventional risk factors. RECENT FINDINGS: Numerous studies support high lipoprotein(a) as an independent risk factor for PAD, AAA, and MALE...
November 1, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39110081/from-remnant-cholesterol-to-lipoprotein-a-emerging-risk-factors-for-cardiovascular-diseases-beyond-low-density-lipoprotein-erratum
#17
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
September 1, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39110080/device-therapy-for-heart-failure-management
#18
REVIEW
Fouad Chouairi, Allison Levin, Marat Fudim
PURPOSE OF REVIEW: Given the prevalence of heart failure (HF) and the interdisciplinary nature of device therapy, it is paramount that cardiologists not only understand the current landscape of goal-directed medical therapy, but also the ongoing efforts in device development. Thus, we aim to provide a practical overview of the broad approaches being utilized in the burgeoning field of device-based therapies for heart failure. RECENT FINDINGS: Currently, a diverse array of devices for HF treatment is being developed and tested, each targeting distinct aspects of HF pathophysiology...
September 1, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39110079/the-importance-of-optimal-medical-therapy-in-patients-undergoing-lower-extremity-bypass
#19
REVIEW
Clara M Gomez-Sanchez, Michael S Conte
PURPOSE OF REVIEW: The prevalence of peripheral artery disease is growing, with millions of people globally suffering its end-stage manifestation, chronic limb-threatening ischemia (CLTI). Revascularization procedures like lower extremity bypass play a vital role in limb salvage but optimal medical therapy is essential for maximizing the benefit of these procedures and reducing long-term risks of cardiovascular and limb-related events. RECENT FINDINGS: Patients with PAD who undergo lower extremity bypass warrant a comprehensive approach to risk factor modification for both primary and secondary prevention of cardiovascular and limb-related complications...
September 1, 2024: Current Opinion in Cardiology
https://read.qxmd.com/read/39110078/revived-bcis-2-update-and-key-learnings
#20
REVIEW
Tesfamariam Aklilu Betemariam, Holly Morgan, Divaka Perera
PURPOSE OF REVIEW: This review summarises the shifting paradigms in the treatment of ischemic left ventricular dysfunction, spotlighting the revascularization for ischemic ventricular dysfunction-British cardiovascular intervention society-2 (REVIVED-BCIS2) trial results and its impact on key therapeutic goals: survival, left ventricular function, arrhythmia prevention, quality of life and viability testing. RECENT FINDINGS: The REVIVED-BCIS2 trial, and its subsequent sub studies highlighted that (PCI) does not provide additional benefits to optimal medical therapy in terms of improving survival, left ventricular (LV) function, arrhythmic risk or quality of life...
September 1, 2024: Current Opinion in Cardiology
journal
journal
29307
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.